Currently, prognosis in patients with FL is assessed using clinical scores such as the Follicular Lymphoma International Prognostic Index (FLIPI), which incorporates age, disease stage ...

High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J. Clin. Oncol. 21, 3918–3927 (2003).

Progression Within 24 Months Predicts Poorer Survival Following Relapse or Progression in Follicular Lymphoma Patients with FL who experience disease progression within 24 months of first-line ...

Laurie Adami's experience with CAR T-cell therapy highlights its potential in treating Non-Hodgkin Lymphoma, emphasizing the ...

Because both of these cancers are typically slow-growing, both trials looked at overall response and complete response rates rather than survival rates. For the follicular lymphoma trial ...

Follicular lymphoma is the second most common form ... and it has a five-year survival rate of only 20% for patients in the third line and later. The new use is the third for Kymriah ...

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the CD19-directed CAR T cell therapy, which is already approved in the EU for certain lymphomas, be authorised to treat ...

Although CAR T-cell therapies have been found effective against certain difficult-to-treat malignancies, they are not devoid of safety concerns.

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...